Company intelligence / Profile preview
HOX Therapeutics
Guildford*, England or Surrey*, United Kingdomhoxtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
HOX Therapeutics is a preclinical-stage biotechnology company developing highly targeted medicines for the treatment of cancer. The company has announced collaborations to identify small molecule inhibitors against undisclosed oncology targets but has not yet reported clinical results.
- No clinical data available as all programs are in preclinical stages.
- Therapeutic areas
- Oncology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Vernalis (R&D) Ltd / HitGen Inc. – Collaboration to identify inhibitors against an undisclosed oncology target using fragment-based drug discovery platforms.
Beyond the preview
Go deeper on HOX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HOX Therapeutics.